Leishmaniasis is a parasitic disease caused by an infection by Leishmania parasites that are transmitted by the bite of infected female sand flies. The disease has many clinical manifestations ranging from self-healing skin lesions to fatal visceralizing illness if left untreated. Leishmaniasis treatment includes drugs such as pentavalent antimonials, amphotericin B formulations, miltefosine, and paromomycin. The global Leishmaniasis treatment market is driven by the rising prevalence of the disease across tropical and subtropical regions due to factors such as urbanization, migration, and agricultural encroachment. The disease has emerged as an important public health problem in several countries and there is an urgent need for new treatment methods.

The Global Leishmaniasis Treatment Market Size is estimated to be valued at US$ 79.95 Bn in 2024 and is expected to exhibit a CAGR of 22% over the forecast period 2024 to 2030.

Key Takeaways

Key players operating in the Leishmaniasis treatment are Johnson & Johnson, Intrabio, Cyclo Therapeutics, Inc., Kempharm, Inc., Azafaros B.V., StrideBio. Sarepta Therapeutics, Inc. The key players are focusing on developing new drugs with novel mechanisms of action and formulations with higher efficacy and safety profiles.

The demand for Leishmaniasis treatment is expected to rise significantly during the forecast period owing to the growing disease burden. As per the World Health Organization (WHO), each year new cases of Leishmaniasis infection add up to 1-1.5 million globally. The changing environmental and climate conditions are facilitating the geographical expansion of the sand fly vectors, propelling the need for effective treatment and control measures.

Technological advancements are expected to boost the Leishmaniasis treatment market during the forecast period. Developments such as new drug delivery technologies can help minimize drug resistance and toxicity issues. Areas such as therapeutic vaccines, gene silencing technology, nanomedicine, and immunotherapy are being explored to develop next-generation drugs for better management of Leishmaniasis.

Market Trends

Increasing collaboration between drug manufacturers and research institutes: This allows leveraging of combined technical expertise for faster development of new drugs for Leishmaniasis. For instance, an alliance between Drugs for Neglected Diseases initiative and Sanofi is working on a combination therapy for Leishmaniasis.

Launch of combination therapies: Given the challenge of drug resistance, combination drug therapies are emerging as a key trend. For instance, the combination of paromomycin with gentamicin or meglumine antimoniate is showing promise for overcoming resistance.

Market Opportunities
Development of new drugs and formulations: There is a need for safer and shorter treatment options with new mechanisms of action. Areas such as nanomedicine, immunotherapy holds promise but require further research.
Undertrials diseases strains: Many Leishmania strains remain untreatable. Opportunities exist in developing effective therapies for resistant strains prevalent in certain regions. Developing regional or country-specific treatment guidelines can help address this unmet need.

Impact of COVID-19 on Leishmaniasis Treatment Market:

The COVID-19 pandemic has impacted the growth of the leishmaniasis treatment market. During the initial outbreak, research activities related to developing new treatments were slowed down as resources were diverted towards COVID-19. This impacted the clinical trials for new drugs in the pipeline which were either postponed or put on hold. The supply chain disruptions also led to non-availability of key drugs for treatment. Access to treatment centres was also restricted during lockdowns to curb the spread of coronavirus. However, with the easing of restrictions, the market is expected to bounce back. Pharmaceutical companies are now accelerating their efforts to develop novel treatments by focusing on immunotherapy, vaccines and parasite genetic studies. Teleconsultations have also picked up which has ensured continued care for patients during the pandemic. The demand for over-the-counter drugs is also increasing. With rapid vaccination drives worldwide and economies opening up gradually, the leishmaniasis treatment market is projected to witness strong growth in the post-pandemic era on the back of resumption of business activities and increased government priorities for infectious disease treatment.

East and South Asia Region:

The East and South Asia region accounts for a major share of the global leishmaniasis treatment market in terms of value. This is due to the high prevalence of various forms of leishmaniasis across countries like India, Bangladesh and Nepal. According to WHO estimates, over 1.5 million new cases occur annually in this region. Countries like India bear more than half of the visceral leishmaniasis disease burden globally. The tropical and subtropical climate coupled with poor sanitation and lack of healthcare infrastructure in rural areas has contributed to the spread of the sandfly vector. Hence, the demand for drugs to treat cutaneous and visceral leishmaniasis is concentrated highly in East and South Asia. Government investments to improve diagnostic capabilities and rollout of awareness campaigns are expected to further fuel market growth in this region over the coming years.

Africa Region:

The Africa region is poised to exhibit the fastest growth in the leishmaniasis treatment market over the forecast period. This can be attributed to rising cases of cutaneous leishmaniasis across endemic countries like Sudan, Ethiopia and South Sudan. According to a WHO report, around 0.2-0.4 million cases of CL occur annually in the African region. Factors such as population movement, urbanization, conflicts and environmental changes are increasing the geographical distribution of the disease here. With limited treatment options currently available, countries like Sudan are prioritizing development of novel indigenous drugs and vaccines. Increasing healthcare expenditures, availability of generic drugs and availability of international aid are expected to boost the demand for leishmaniasis treatment drugs in Africa over the next few years.

Get More Insights On This Topic: https://www.pressreleasebulletin.com/leishmaniasis-treatment-market-forecast-outlook-trend-2023-2030-2/